ClinicalTrials.govpublic full text
Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
b-all, dlbcl, b all, dlbcl-ci, dlbcl unclassifiable, dlbcl, nos genetic subtypes, dlbcl activated b-cell type, dlbcl germinal center b-cell type, diffuse large b-cell lymphoma, hgbl, hgbl, nos, cd19+ b-cell malignancy
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Record · ID 917148
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.